The word “transformational” is used all too frequently in market updates and annual reports, so much so that for many an investor it can lead to a subconscious eye roll. However, Destiny Pharma finds itself at a juncture that can justifiably be labelled as transformational. Dependant on how matters develop, that transformation could be either good or bad for the company. The principle driver of interest in Destiny right now is anticipation of XF-73 Phase 2b results which are due before the end of March 2021. There has been a surge of interest and a corresponding surge in share price since a December update confirming the recruitment process for the trials had completed.